https://www.selleckchem.com/products/repsox.html
ectivity of patients with mild-to moderate disease. In case IFNβ-1a reduced the duration of hospital stay and/or ameliorated the clinical status, it may become a cornerstone of COVID-19 treatment. EudraCT 2020-002458-25. Registered on May 11, 2020 ClinicalTrials.gov Identifier NCT04449380. EudraCT 2020-002458-25. Registered on May 11, 2020 ClinicalTrials.gov Identifier NCT04449380. Children with COVID 19 infection (CV19) generally have a mild disease whose main symptoms are fever and cough. Dyspnoea and hypoxemia are rarely reported and
Like
Comment
Share
